2 CH2), 2.34 (s, 3 H, p-aryl-CH3), 1.95 (s, 6 H, o-aryl-CH3), 0.94
(t, 3J (HH) = 6.9 Hz, 6 H, 2 CH3). 13C NMR (75 MHz, CD2Cl2)
d/ppm: 181.3 (NCN), 139.7 (p-aryl-C), 136.2 (i-aryl-C), 135.3
(o-aryl-C), 129.6 (m-aryl-C), 122.9 (CH), 122.4 (CH), 54.6 (CH2),
51.2 (CH2), 47.8 (N(CH2)2), 21.3 (p-aryl-CH3), 17.8 (o-aryl-CH3),
12.5 (CH3). MS(FAB+): m/z = 392.1256 for C18H27N3Ag [M -
Cl]+.
[(1-(2-N ,N -dimethylamino)-ethylene-3-mesityl)imidazol-2-
ylidene] palladium(II) methyl chloride (5a). A procedure from the
literature13 was modified as follows: palladium(II) methyl chloride
cyclooctadiene (1.0 equivalent) and bis(imidazol-2-ylidene) silver
complex (0.5 equivalent) were suspended in dry dichloromethane
to 0.1 M and stirred at room temperature for 2 h under an
atmosphere of dry nitrogen. The reaction mixture was then
filtered over a pad of Celite, which was washed with 10 mL dry
dichloromethane. The solution was concentrated and the residue
was then washed three times with 10 mL dry diethyl ether. The
product (126 mg, 86%) was obtained as an off-white microcry-
stalline solid. H NMR (300 MHz, CD2Cl2) d/ppm: 7.09 (d, J
(HH) = 2 Hz, 1 H, CH), 6.96 (s, 2 H, aryl-CH), 6.79 (d, 3J (HH) =
2 Hz, 1 H, CH), 4.19 (m, 2 H, N-CH2), 2.63 (s, 6 H, N(CH3)2), 2.42
(m, 2 H, Im-CH2), 2.31 (s, 3 H, p-aryl-CH3), 2.18 (s, 6 H, o-aryl-
CH3), -0.16 (s, 3 H, PdCH3). 13C NMR (75 MHz, CD2Cl2) d/ppm:
170.9 (NCN), 139.1 (p-aryl-C), 136.6 (i-aryl-C), 134.9 (o-aryl-C),
129.4 (m-aryl-C), 123.1 (CH), 121.2 (CH), 63.3 (CH2), 49.4 (CH2,
N(CH3)2), 21.2 (p-aryl-CH3), 18.8 (o-aryl-CH3), -12.2 (Pd-CH3).
MS(FAB+): m/z = 378.1170 for C17H26N3Pd [M - Cl]+.
Bis[(1-(2-N,N-diisopropylamino)-ethylene-3-mesityl)imidazol-
2-ylidene] silver(I) dichloride (1c). The product (236 mg, quantita-
tive yield) was obtained as colourless crystals. 1H NMR (300 MHz,
3
1
3
CD2Cl2) d/ppm: 7.23 (d, J (HH) = 1.7 Hz, 1 H, CH), 6.99 (s,
2 H, aryl-H), 6.91 (d, 3J (HH) = 1.7 Hz, 1 H, CH), 4.14 (bs, 2 H,
3
i
N-CH2), 3.02 (septet, J (HH) = 6.6 Hz, 2 H, Pr-CH), 2.85 (bs,
2 H, Im-CH2), 2.34 (s, 6 H, p-aryl-CH3), 1.96 (bs, 6 H, o-aryl-CH3),
3
i
0.95 (d, J (HH) = 6.6 Hz, 12 H, Pr-CH3). 13C NMR (75 MHz,
CD2Cl2) d/ppm: 182.3 (NCN), 139.8 (p-aryl-C), 136.1 (i-aryl-C),
135.5 (o-aryl-C), 129.0 (m-aryl-C), 123.1 (CH), 122.1 (CH), 54.7
(CH2), 48.5 (CH2), 46.7 (N(CH)2), 21.5 (p-aryl-CH3), 21.0 (CH3),
17.8 (o-aryl-CH3). MS(FAB+): m/z = 420.1411 for C20H29N3Ag
[M - Cl]+.
General procedure for the one-pot synthesis of palladium(II) methyl
chloride NHC complexes
Bis[(1-(2-N-pyrrolidinyl)-ethylene-3-mesityl)imidazol-2-ylidene]
silver(I) dichloride (1d). The product (246 mg, 92%) was obtained
1
as a sticky yellow solid. H NMR (300 MHz, CD2Cl2) d/ppm:
Imidazolium salt, silver(I) oxide (1.0 equivalent) and palladium
methyl chloride cyclooctadiene (1.0 equivalent) were suspended
in dry dichloromethane and stirred with activated molecular
sieves overnight at room temperature under an atmosphere of
dry nitrogen. The reaction mixture was then filtered over a pad of
Celite, which was washed with 10 mL dry dichloromethane. The
filtrate was then concentrated and washed three times with 10 mL
dry diethyl ether.
3
7.35 (d, J (HH) = 1.8 Hz, 1 H, CH), 7.02 (s, 2 H, aryl-CH),
6.96 (d, 3J (HH) = 1.8 Hz, 1 H, CH), 4.30 (t, 3J (HH) = 6.0 Hz,
3
3
2 H, CH2), 2.93 (t, J (HH) = 6.0 Hz, 2 H CH2), 2.58 (m, J
(HH) = 2.4 Hz, 4 H, pyrrolidinyl), 2.37 (s, 3 H, p-aryl-CH3), 1.99
(s, 6 H, o-aryl-CH3), 1.77 (m, 3J (HH) = 1.8 Hz, 4 H, pyrrolidinyl).
13C NMR (75 MHz, CD2Cl2) d/ppm: 181.3 (NCN), 140.0
(p-aryl-C), 136.2 (o-aryl-C), 137.2 (i-aryl-C), 129.7 (m-aryl-C),
122.7 (CH), 122.1 (CH), 57.1 (pyrrolidinyl), 54.7 (CH2), 51.6
(CH2), 24.1 (pyrrolidinyl), 21.3 (p-aryl-CH3), 17.9 (o-aryl-CH3).
MS(FAB+): m/z = 673.3149 for C36H50N6Ag [(NHC)2Ag]+.
[(1-(2-N ,N -dimethylamino)-ethylene-3-mesityl)imidazol-2-
ylidene] palladium(II) methyl chloride (5a). The product (183 mg,
81%) was obtained as an off-white microcrystalline solid.
Bis[(1-(2-N,N-dimethylamino)-ethylene-3-(4-methoxyphenyl))
imidazol-2-ylidene] silver(I) dichloride (2). The product (284 mg,
[(1-(2-N ,N -diethylamino)-ethylene-3-mesityl)imidazol-2-
ylidene] palladium(II) methyl chloride (5b). The product (128 mg,
92%) was obtained as a yellow solid. 1H NMR (300 MHz, CD2Cl2)
d/ppm: 7.06 (d, 3J (HH) = 2.1 Hz, 1 H, CH), 6.98 (s, 2 H, aryl-
1
76%) was obtained as a brown/green oil. H NMR (300 MHz,
CD2Cl2) d/ppm: 7.49 (m, 2 H, aryl-H), 7.31 (d, 3J (HH) = 2.1 Hz,
1 H, CH), 7.24 (d, 3J (HH) = 2.1 Hz, 1 H, CH), 7.03 (m, 2 H, aryl-
3
H), 6.80 (d, J (HH) = 2.1 Hz, 1 H, CH), 4.25 (m, 2 H, CH2),
3
H), 4.26 (t, J (HH) = 6 Hz, 2 H, N-CH2), 3.87 (s, 3 H, OCH3),
3.40–2.80 (2 broad multiplets, 4 H, CH2), 2.66 (m, 2 H, CH2), 2.35
(s, 3 H, p-aryl-CH3), 2.17 (s, 6 H, o-aryl-CH3), 1.26 (t, 3J (HH) =
7.2 Hz, 6 H, CH3), -0.05 (s, 3 H, Pd-CH3). 13C NMR (75 MHz,
CD2Cl2) d/ppm: 169.7 (NCN), 139.2 (p-aryl-C), 136.6 (i-aryl-C),
135.1 (m-aryl-C), 129.3 (o-aryl-C), 123.3 (CH), 120.8 (CH), 53.4
(CH2), 52.8 (N(CH2)2), 50.7 (CH2), 21.2 (p-aryl-CH3), 18.8 (o-aryl-
CH3), 11.4 (CH3), -11.7 (Pd-CH3). MS(FAB+): m/z = 406.1486
for C19H30N3Pd [M - Cl]+.
2.72 (t, 3J (HH) = 6 Hz, 2 H, Im-CH2), 2.29 (s, 6 H, N-Me). 13
C
NMR (75 MHz, CD2Cl2) d/ppm: 179.8 (NCN), 160.4 (p-aryl-C),
133.7 (i-aryl-C), 126.0 (o-aryl-C), 122.4 (CH), 122.1 (CH), 115.1
(m-aryl-C), 60.4 (OCH3), 56.1 (CH2), 50.5 (CH2), 45.7 (N(CH3)2).
MS(FAB+): m/z = 352.0572 for C14H19N3OAg [M - Cl]+.
Bis[(1-(2-N,N-dimethylamino)-ethylene-3-(4-N,N-dimethyl-
phenyl))imidazol-2-ylidene] silver(I) dichloride (3). The product
(180 mg, 76%) was obtained as a brown solid. 1H NMR (300 MHz,
[(1-(2-N -pyrrolidinyl)-ethylene-3-mesityl)imidazol-2-ylidene]
palladium(II) methyl chloride (5d). The product (0.068 g, 66%)
3
CD2Cl2) d/ppm: 7.39 (d, J (HH) = 9 Hz, 2 H, aryl-H), 7.28
3
3
1
(d, J (HH) = 1.8 Hz, 1 H, CH), 7.21 (d, J (HH) = 1.8 Hz,
was obtained as a white powder. H NMR (300 MHz, CD2Cl2)
3
3
1 H, CH), 6.78 (d, J (HH) = 9 Hz, 2 H, aryl-H), 4.24 (t, J
(HH) = 9 Hz, 2 H, N-CH2), 3.01 (s, 6 H, aryl-N(CH3)2), 2.71 (d,
3J (HH) = 9 Hz, 2 H, Im-CH2), 2.29 (s, 6 H, N(CH3)2). 13C NMR
(75 MHz, CD2Cl2) d/ppm: 179.5 (NCN), 151.1 (p-aryl-C), 129.7
(i-aryl-C), 125.4 (o-aryl-C), 122.3 (CH), 122.1 (CH), 112.7 (m-aryl-
C), 60.5 (CH2), 50.5 (CH2), 45.9 (N(CH3)2), 40.8 (aryl-N(CH3)2).
MS(FAB+): m/z = 365.0893 for C15H22N4Ag [M - Cl]+.
d/ppm: 7.05 (d, 3J (HH) = 2.1 Hz, 1 H, CH), 7.00 (s, 2 H, aryl-
3
CH), 6.84 (d, J (HH) = 2.1 Hz, 1 H, CH), 4.22 (m, 2 H, CH2),
3.79 (m, 2 H, CH, pyrrolidinyl), 2.71 (m, 2 H, CH, pyrrolidinyl),
2.44 (m, 2 H, CH2), 2.35 (s, 3 H, p-aryl-CH3), 2.22 (s, 6 H, o-aryl-
CH3), 1.80 (m, 4 H, CH2, pyrrolidinyl), -0.13 (s, 3 H, Pd-CH3).
13C NMR (75 MHz, CD2Cl2) d/ppm: 170.0 (NCN), 139.3
(p-aryl-C), 137.3 (i-aryl-C), 134.8 (o-aryl-C), 129.6 (aryl-CH),
7084 | Dalton Trans., 2009, 7080–7086
This journal is
The Royal Society of Chemistry 2009
©